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Targeting peptideThe novel peptidasome, called presequence protease, PreP, was originally identiﬁed and characterized in
Arabidopsis thaliana as a mitochondrial matrix and chloroplast stroma localized metalloprotease. PreP has
a function as the organellar peptide clearing protease and is responsible for degrading free targeting peptides
and also other unstructured peptides up to 65 amino acid residues that might be toxic to organellar
functions. PreP contains an inverted Zn-binding motif and belongs to the pitrilysin protease family. The
crystal structure of AtPreP reﬁned at 2.1 Å demonstrated a unique totally enclosed large cavity of 10000 Å3
that opens and closes in response to peptide binding, revealing a novel catalytic mechanism for proteolysis.
Homologues of PreP have been found in yeast and human mitochondria. Interestingly, the human PreP,
hPreP, is the protease that is responsible for clearing the human brain mitochondria from the toxic amyloid-
β peptide (Aβ) associated with Alzheimer's disease (AD). Accumulation of Aβ has been shown in the brain
mitochondria from AD patients and mutant transgenic mice overexpressing Aβ. Here, we present a review of
our present knowledge on structural and functional characteristics of PreP and discuss its mitochondrial Aβ-
degrading activity in the human brain mitochondria in relation to AD.6 8 153679.
ll rights reserved.© 2010 Elsevier B.V. All rights reserved.1. Introduction
Mitochondrial dysfunction is believed to play an important role in
human diseases, such as diabetes, cancer and neurodegenerative
disorders such as Alzheimer's disease and Parkinson disease [1–3].
Hence, the organelle has specialized scavenging systems for its
protection [4]. A set of mitochondrial proteases conducts protein
quality control, which is of importance for the biogenesis, morphology
and homeostasis of mitochondria. The proteases requiring ATP for
their action have been found in different mitochondrial sub-
compartments. They are responsible for clearance of non-assembled,
misfolded and damaged proteins thereby preventing accumulation of
these proteins and possible deleterious effects on mitochondria [5].
The energy derived from ATP is utilized for transport of a substrate
into the catalytic chamber and to unfold speciﬁc substrates [6]. The
ATP dependent proteases catalyse the ﬁrst step of degradation by
cleaving proteins into peptides that thereafter are degraded to free
amino acids by non-ATP dependent proteases.
Presequence protease, PreP, is an ATP-independent protease that
was ﬁrst identiﬁed and characterized as a mitochondrial matrix and
chloroplast stroma metalloendopeptidase in Arabidopsis thaliana, At-
PreP, responsible for degradation of mitochondrial presequences and
chloroplast transit peptides that are generated after organellar
precursor protein import and processing [7–9]. PreP is a member ofpitrilysin family of proteases containing an inverted zinc-binding
motif, HXXEH and has been shown to degrade not only targeting
peptides but also other unstructured peptides. PreP is a general
protease and homologues of this protease are present in all species
except among archea. Interestingly, PreP is an organellar functional
analogue to insulin degrading enzyme (IDE), which also belongs to
the pitrilysin family. IDE has received a lot of attention due to its
implication in Alzheimer's disease (AD) as it can degrade the toxic
amyloid-β peptide (Aβ) associatedwith this disease [10,11]. Although
the amyloid plaques characteristic of AD consist of extracellular
aggregates of the toxic Aβ peptide, there are several lines of evidence
implicating that Aβ peptide may exert its toxicity within the cell
[12,13] and point towards a central role of mitochondria in this
process [14].
Interestingly, we have been able to show that the human PreP,
hPreP, is the protease responsible for degrading the toxic Aβ inside
mitochondrial matrix of the human brain mitochondria [15]. Here we
present a fascinating research journey starting from identiﬁcation of
PreP in A. thaliana as the mitochondrial presequence degrading
protease to its role as the Aβ-degrading protease in the human brain
mitochondria with a possible relation to the pathology of AD.
2. Presequence protease, PreP, a novel organellar peptidasome
The vast majority of mitochondrial proteins are nuclear encoded
and synthesized in the cytosol as precursor proteins. The precursor
proteins that are destined to the mitochondrial matrix as well as a
number of proteins of the innermembrane and inter membrane space
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the import of the precursor into the matrix the presequence is no
longer needed and is therefore cleaved off by the mitochondrial
processing peptidase (MPP) [16,17] resulting in the production of the
mature protein and a free presequence. The free presequences have to
be removed since they can penetrate the mitochondrial inner
membrane, dissipate membrane potential and uncouple respiration
and are therefore potentially harmful for the integrity and function of
mitochondria [18].
2.1. Identiﬁcation of PreP
The ﬁrst experimental evidence for degradation of presequences
was obtained by Ståhl et al. [9] demonstrating a rapid degradation of
the presequence of F1β subunit of ATP synthase by a matrix localized
ATP-independent protease after precursor import and processing in
Solanum tuberosum mitochondria. PreP, was isolated from the
mitochondrial matrix by a three-step chromatographic procedure
including afﬁnity and anion exchange chromatography and identiﬁed
by mass spectrometric analysis, ESI-MS/MS, [8] in the A. thaliana
database as a novel organellar zinc metalloprotease containing an
inverted zinc-binding motif (HXXEH) belonging to the pitrilysin
protease family (subfamily M16C). There are two isoforms of PreP
present in A. thaliana, AtPreP1 and AtPreP2, displaying high amino
acid sequence similarities, with most difference in their N-terminal
cleavable presequences, which are predicted to be 85 amino acids
long for both isoenzymes. Immunological studies of isolated sub-
fractionated mitochondria and chloroplasts from Spinacia oleracea
revealed that PreP is not only present in mitochondria, but also in
chloroplasts as a stromal protein [7]. The AtPreP was overexpressed in
E. coli and the recombinant protein was characterized with respect to
physicochemical properties, catalytic site, substrate speciﬁcity and
intracellular localization. The protease was puriﬁed as a dimer with a
molecular mass of 110 kDa of the monomer and showed broad
temperature and pH optima. Mutagenesis studies of the residues
involved in metal binding conﬁrmed the essential role of the
histidines and glutamate for the proteolytic activity [7].
2.2. Substrate speciﬁcity of PreP
Substrate speciﬁcity studies revealed that the recombinant AtPreP
does not recognize amino acid sequence per se and that it degrades
mitochondrial and chloroplast targeting peptides, such as e.g. the
presequence of the F1β subunit of themitochondrial ATP synthase and
the transit peptide of the small subunit of Rubisco as well as other
non-related unstructured peptides including insulin B-chain, galanin,
penetratin, human prion protein peptide hPrPss1–28, Cecropin A1–33, a
ﬂuorescent synthetic peptide C11–11 and ﬂuorogenic peptide derived
from bradykinin called Substrate V, coupled to ﬂuorescent 7-
methoxycoumarin quenched by 2,4-dinitrophenol [7,19]. Both AtPreP1
andAtPreP2 cleaved peptides that are in the range of 10 to 65 amino acid
residues, whereas folded or longer unfolded peptides and small proteins
were not degraded. Detailed substrate speciﬁcity studies showed that
both proteases have preference for positively charged amino acids in the
P1′ position and small-uncharged residues or serine residues in the P1
position. Despite the fact that there were similarities in substrate
speciﬁcity, mapping of the cleavage sites showed unique cleavage
patterns that were context and structure dependent for both AtPreP
isoforms [20].
2.3. Localization, import properties and deletion of PreP in A. thaliana
Both AtPreP1 and AtPreP2 are located to mitochondria as well as
chloroplasts. Studying in vitro import of AtPreP precursor proteins
and in vivo import of fusion constructs consisting of wild type and
mutated forms of the N-terminal portion of AtPreP1 and AtPreP2coupled to GFP (Green Fluorescent Protein), we have demonstrated
that both isoenzymes are dually targeted to both organelles using
an ambiguous targeting signal [7,20–22]. Furthermore, deletion of
28 amino-terminal residues from the AtPreP1 precursor protein
resulted in import only into chloroplasts, whereas the mitochon-
drial import was completely abolished, indicating a domain
structure of the AtPreP1 targeting peptide [21].
In A. thaliana plants, both AtPreP1 and AtPreP2 are expressed in all
tissues (ﬂowers and siliques have the highest expression), but At-
PreP1 is expressed to a much higher level than AtPreP2. Whereas the
single atprep2 mutant did not show any phenotype, the deletion of
atprep1 resulted in a phenotype both on the morphological and
cellular level, especially during early plant development. Double
knockout mutant plants exhibited a chlorotic phenotype and a slower
growth rate. The accumulated biomass was 40% lower all through the
development in the mutant plants in comparison to wild type. Both
mitochondria and chloroplasts exhibited altered morphology. Chlor-
oplasts contained less grana stacking and less starch granules,
chlorophyll a and b content in true leaves was diminished.
Mitochondria were variable in size, partially uncoupled and the
respiratory rates were lower [23]. These results demonstrate the
importance of PreP for efﬁcient organellar functions and normal plant
growth and development.
2.4. 3D structure of PreP and mechanism of catalysis
The crystal structure of the recombinant inactive mutant AtPreP1
E80Q, where the Glu in the metal binding motif HXXEH was changed
to Gln, has been solved at 2.1 Å resolution [24]. This structure
represented the ﬁrst closed conformation of a protease from the
pitrilysin family with a substrate bound to it. The AtPreP polypeptide
folds into four topologically similar domains, creating bowl-shaped
halves, which are connected by a unique hinge region consisting of 82
residues. These two halves in PreP create a large internal chamber of
about 10000 Å3, where the active site resides. The ﬁrst domain
harbours the major part of active site since it contains the inverted
zinc-binding motif (HXXEH) where the His77 and His81 coordinate
the zinc atom and Glu80 acts a base catalyst. Additional important
residue found on the basis of solved structure is the third zinc ligand
called the distal Glu177. Moreover, Arg848 and Tyr854 located in the
C-terminal part of the enzyme, at a distance of almost 800 amino acid
residues from the zinc-binding motif, form hydrogen bonds with the
substrate and thereby complete the catalytic chamber. The chamber is
spacious enough to accommodate peptide substrates such as
presequences but not larger, folded proteins. As the active site
includes residues from both the N-terminal and C-terminal portion of
the protein, degradation activity occurs only when the proteolytic
chamber is closed. Even though the protease was crystallized in the
absence of a substrate, the electron density revealed a six amino acid
peptide bound in the active site. Based on the 3D structure of MPP
[25], that exhibits similar fold as PreP despite very low sequence
similarity, modeling of the open conformation of the enzyme has been
performed and a novel mechanism for proteolysis was proposed. This
mechanism involves hinge-bending motions causing opening and
closing of the enzyme in response to substrate binding (Fig. 1.) [24].
Cysteine double mutants of AtPreP generated for locking the enzyme
in a closed conformation demonstrated an inhibited proteolytic
activity when disulphide bridges were formed under oxidizing
condition, whereas the activity was normal in the absence of
disulphide bonds. These experiments strongly supported the novel
proteolytic mechanism of PreP [24]. As enclosure of substrates inside
the catalytic chamber is reminiscent of the proteasome, we have
referred to PreP as a peptidasome.
Interestingly, crystallization of AtPreP was only possible in the
presence of Mg2+ and the structure revealed that there are two Mg2+
binding sites present in the 3D structure of AtPreP, one located inside
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surface of the enzyme (the outer site) [24]. The proteolytic activity
was inhibited in the absence of Mg2+ showing the importance of this
divalent metal for AtPreP function. Upon addition of MgCl2 and CaCl2
the proteolytic activity was regained with full activation at about
1 mM MgCl2 and 0.1 mM CaCl2 [19]. Mutating one or both metal
binding sites that rendered the enzyme unable to bind Mg2+ showed
that this non-catalytic metal binding was essential for the enzyme
activity. When the inner metal binding site was removed the
degradation activity of AtPreP against several unstructured peptides
of different lengths and amino acid compositions as substrates was
abolished [19].
2.5. Yeast homologue of PreP
Homologues of PreP are present in all species except among
archea. The homologue of AtPreP in Saccharomyces cerevisiae,
Mop112 has been identiﬁed and localized to the intermembrane
space (IMS) of mitochondria in contrast to plants and mammalian
mitochondria (see below), where PreP is found in the matrix [7,26].
Mop112 has much shorter presequence, which is 7 amino acids long
[27] than AtPreP (85 amino acids) and the import of Mop112 is not
dependent on Tim23 but requires membrane potential (Δψ). Deletion
of MOP112 gene in S. cerevisiae leads to slower growth and increased
peptide export out from the organelle when grown on a non-
fermentable carbon source. The exported peptides were either
generated upon proteolysis of mitochondrial proteins or they were
presequence peptides cleaved off by processing peptidases. This
shows that despite different intra-mitochondrial localization, Mop112
exerts a similar function as PreP. Furthermore, our recent preliminary
studies show that AtPreP complements MOP112 deleted yeast strains
suggesting that a matrix located enzyme can rescue the function of an
IMS localized protein with a similar catalytic activity (Alikhani et al.,
unpublished).
The human PreP homologue, hPreP and its relation to Alzheimer's
disease will be discussed below.
3. Mitochondria and Alzheimer's disease
Alzheimer's disease (AD) is a progressive neurodegenerative
disorder characterized by intracellular neuroﬁbrillary tangles and
senile plaques in the brain. The major constituent of a senile plaque is
the Aβ peptide [28]. Aβ is produced by regulated intramembrane
proteolysis of the amyloid precursor protein (APP) by the sequentialFig. 1.Mechanism of PreP catalyzed proteolysis [24]. Substrate peptide binds to the enzyme i
presentation of AtPreP in a closed conformation as described by Johnson et al. [24] and in acleavage by β- and γ-secretases [29,30]. Aggregation of Aβ into
oligomers and ﬁbrils causes toxicity, loss of synapses and ultimately
neuronal death [31–33]. Although the amyloid plaques characteristic
of AD consist of extracellular aggregates of the toxic Aβ peptide,
accumulating data show that Aβ peptidemay exert toxicity within the
cell [12,13] and several lines of evidence highlight the role of
mitochondria in this process [14]. Recent studies have shown
accumulation of Aβ in the brain mitochondria of AD patients and
mutant transgenic APP mice [34,35]. The Aβ accumulation in
mitochondria impairs neuronal function and contributes to cellular
dysfunction and elevated oxidative stress. The enzymatic activity of
cytochrome c oxidase (COX), complex IV of the electron transfer chain
has been shown to be diminished in AD brain mitochondria and in the
presence of Aβ [36,37]. Furthermore, mitochondrial Aβ-binding
alcohol dehydrogenase (ABAD) has been found to be up-regulated
in neurons from AD patients and Aβ has been shown to interact with
ABAD resulting in free radical production and neuronal apoptosis [35].
Data have also shown the interaction of Aβwith cyclophilin D (CypD),
an integral part of the mitochondrial permeability transition pore,
causing elevated oxidative stress and apoptosis [38,39]. Furthermore,
Aβ has been found in the brain mitochondria of living patients with
plaque pathology. APP has been found to be arrested and accumulated
in the translocase of the outer membrane (TOM) machinery of the
human AD brain mitochondria probably due to the presence of the
acidic region between residues 220–290 in APP, which prevents full
translocation into mitochondria, leaving the bigger portion that
includes and generate Aβ in the cytosol [40–42]. Due to the
incomplete import of APP into mitochondria, Aβ most probably
cannot be generated inside mitochondria and therefore needs to be
imported into the organelle. Our study showed that extracellular Aβ
can be taken up by neuroblastoma cells and that it was found to be
localized in the mitochondria. Moreover, Aβ40 and Aβ42 have been
shown to be transported into mitochondria via the TOM machinery
[43]. Aβ has been found to reside both in the inner membrane and in
the matrix, however the mode of its translocation across the inner
membrane has not been elucidated [43]. Aβ interactingmitochondrial
proteins and protein complexes are illustrated in Fig. 2.
4. The human mitochondrial Aβ-degrading protease, hPreP
It has been demonstrated that human PreP, hPreP, is the
mitochondrial Aβ-degrading protease, in human brain mitochondrial
matrix. hPreP was originally identiﬁed as human metalloprotease 1,
hMp1 [44], which consists of 1037 amino acids (AAH05025) and isn an open conformation, but catalysis can only occur when the enzyme is closed. Ribbon
n open conformation based on homology modeling from the 3D structure of MPP [47].
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matic prediction programs predicted hPreP to harbour a 29 amino
acids mitochondrial targeting presequence and intra-mitochondrial
localization studies demonstrated hPreP to be localized in the
mitochondrial matrix in mammals [15]. In addition, proteome studies
of human mitochondria have conﬁrmed the mitochondrial localiza-
tion of hPreP [45]. Thus, hPreP (and rat PreP) appears to have similar
sub-mitochondrial localization as plant PreP [7,15], the mitochondrial
matrix, but different than the yeast homologue Mop112 that is
localized to the IMS [26].
hPreP has the ability to degrade, Aβ40 and Aβ42 as well as the
Arctic Aβ40 (E22G), the peptide that is associatedwith increased early
onset protoﬁbril formation in FAD (Familial AD) caused by a mutation
in the APP gene. Analysis of PreP-mediated degradation pattern of
Aβ40 and Arctic Aβ40, by LC-MS/MS, resulted in the generation of
several fragments after cleavage at sites, such as Gln15↓Lys16,
Lys16↓Leu17, Ala30↓Ile31, Gly33↓Leu34 and Leu34↓Met35, which
are exclusive for hPreP. Notably, several of the cleavage sites are
located after the Gly29 in the very hydrophobic C-terminal portion of
the peptides that is prone to aggregation.
In contrast to IDE, hPreP lacks the ability to degrade insulin. It
has been shown that IDE harbours an exosite in the catalytic
chamber, hypothesized to unfold small proteins [46]. The
corresponding site is not found in the PreP structure making PreP
incapable to degrade folded small proteins. Furthermore, data have
shown that hPreP is the sole protease responsible for degradation of
Aβ in mitochondria. Immuno-inactivation studies in situ using anti-
hPreP antibodies abolished the activity against Aβ, proving that
hPreP is the protease in charge of clearing mitochondria from the
toxic Aβ peptides [15].
hPreP shows 48% sequence similarity and 31% identity to AtPreP.
Therefore, the solved 3D structure of AtPreP [24] allowed us to create
a molecular homology model of hPreP. Similar to AtPreP, hPreP
consist of 4 domains, creating two halves that are connected by a
hinge region. The two halves can come together creating a large
catalytic chamber. The inverted zinc-bindingmotif is located in the N-
terminal portion, and residues located in the C-terminal half complete
the active site. Notably, the hPreP homology modeling revealed two
cysteines, Cys90 in the N-terminal portion and Cys527 located in theFig. 2. Mitochondria and Alzheimer's disease: the role of PreP as the mitochondrial Aβ-d
sequence; due to an acidic domain (residues 220–290) it is not completely imported into to o
mitochondria via the TOM complex. The imported Aβ can reside in the inner membrane inhib
it can either be degraded by PreP or it can interact with cyclophilin D or ABAD causing elevhinge region, to be in close vicinity to each other. These cysteines are
conserved in all mammalian PreP sequences as well as inMop112 (the
PreP homologue in S. cerevisiae), but not in AtPreP. Analyzing the
proteolytic activity of hPreP under oxidizing conditions demonstrated
an abolished activity against Aβ, pointing towards a disulphide bridge
formation between Cys90 and Cys527 that locks the enzyme in a
closed conformation and inhibits the substrate to enter the catalytic
chamber. Demonstrating full proteolytic activity of the hPreP(C90S)
and hPreP(C527S) variants under oxidizing conditions conﬁrmed the
involvement of these cysteines in creating disulphide bridges and
causing an inhibition of hPreP function. These ﬁndings are highly
interesting and indicate a possible inhibition of hPreP under elevated
ROS production in mitochondria that is implicated in AD and might
therefore be of physiological importance.5. Concluding remarks
To conclude, our studies show that PreP is the organellar peptide
clearing protease. The clearance of toxic peptides including the
mitochondrial Aβ by PreP may be of importance for mitochondrial
homeostasis and may play a role in the pathology of AD. The elevated
ROS production in mitochondria might inhibit hPreP leading to
accumulation of Aβ, which thereby will cause mitochondrial dys-
function contributing to AD. Therefore, up-regulation of hPreP activity
may prevent the Aβ accumulation and its binding to ABAD and CypD
and thereby rescue the mitochondria from dysfunction and neuronal
apoptosis (see Fig. 2). Further studies of the hPreP activity in AD
brains and in AD transgenic mice models will be of importance for our
understanding of the mechanism behind AD.Acknowledgments
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